|
| PSI-7977-13C-d3 Basic information |
Product Name: | PSI-7977-13C-d3 | Synonyms: | PSI-7977-13C-d3;[13C,2H3]-Sofosbuvir;isopropyl((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-(methyl-13C-d3)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate;Sofosbuvir 13CD3Q: What is
Sofosbuvir 13CD3 Q: What is the CAS Number of
Sofosbuvir 13CD3 Q: What is the storage condition of
Sofosbuvir 13CD3 Q: What are the applications of
Sofosbuvir 13CD3 | CAS: | 2070009-25-3 | MF: | C2113CH26D3FN3O9P | MW: | 0 | EINECS: | | Product Categories: | | Mol File: | Mol File | |
| PSI-7977-13C-d3 Chemical Properties |
storage temp. | Store at -20°C | solubility | DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 25 mg/ml,PBS (pH 7.2): 0.2 mg/ml | form | A solid |
| PSI-7977-13C-d3 Usage And Synthesis |
Description | PSI-7977-13C-d3 is intended for use as an internal standard for the quantification of PSI-7977 by GC- or LC-MS. PSI-7977 is a phosphoramidate prodrug of PSI-7851, a nucleoside analog that, when phosphorylated, inhibits the RNA-dependent RNA polymerase of hepatitis C virus (EC50 = 92 nM). PSI-7977 is effective in vitro and in vivo. | Uses | PSI-7977-13CD3 is the isotope labelled analog of PSI-7977. PSI-7977 is a prodrug that is metabolized to the active antiviral agent 2''-deoxy-2''-α-fluoro-β-C-methyluridine-5''-monophosphate and is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C. Studies have profiled PSI-7977 as a nucleotide inhibitor of hepatitis C virus, exerting selective inhibitory effects towards HCV NS5B polymerase. |
| PSI-7977-13C-d3 Preparation Products And Raw materials |
|